NASDAQ:CNTB Connect Biopharma Q3 2025 Earnings Results & Report $0.90 -0.01 (-1.54%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more. Connect Biopharma missed analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.31 versus the -$0.24 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call9:00 AM ET Connect Biopharma EPS ResultsActual EPS-$0.31Consensus EPS -$0.24Beat/MissMissed by -$0.07One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersConnect Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsConnect Biopharma's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K)Quarterly Report(10-Q) Connect Biopharma Q3 2025 Earnings FAQ Did Connect Biopharma beat earnings estimates for Q3 2025? Connect Biopharma (NASDAQ:CNTB) reported earnings of -$0.31 per share for Q3 2025, missing the consensus estimate of -$0.24. The report was announced on Wednesday, November 12, 2025. When is Connect Biopharma's next earnings date? Connect Biopharma's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Connect Biopharma on the company's earnings history page. Connect Biopharma Earnings HeadlinesConnect Biopharma Holdings Ltd ADR (CNTB)October 13 at 8:31 PM | in.investing.comConnect Biopharma (NASDAQ:CNTB) Given "Outperform" Rating at Leerink PartnersOctober 12 at 8:42 AM | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)Connect Biopharma (NASDAQ:CNTB) and Krystal Biotech (NASDAQ:KRYS) Critical ContrastOctober 12 at 4:28 AM | americanbankingnews.comConnect Biopharma (NASDAQ:CNTB) Earns "Buy" Rating from HC WainwrightOctober 10, 2026 | americanbankingnews.comHC Wainwright Issues Pessimistic Outlook for CNTB EarningsOctober 6, 2026 | americanbankingnews.comSee More Connect Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email. Email Address About Connect BiopharmaConnect Biopharma (NASDAQ:CNTB) Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression. Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Connect Biopharma has also developed rademikibart, formerly known as CBP-201, an antibody targeting the interleukin-4 receptor alpha pathway for immune-mediated conditions including atopic dermatitis and other type 2 inflammatory diseases. Founded in 2012, Connect Biopharma has conducted research and clinical-development activities in the United States and China, with a focus on advancing treatments for patients with significant unmet medical needs. The company is headquartered in San Diego, California, and has historically maintained operations in China as part of its international development and research organization.View Connect Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
